返回 
加入收藏
特瑞普利单抗联合化疗用于局部晚期或转移性NSCLC的快速卫生技术评估
x
请在关注微信后，向客服人员索取文件
| 篇名： | 特瑞普利单抗联合化疗用于局部晚期或转移性NSCLC的快速卫生技术评估 |
| TITLE： | Rapid health technology assessment of toripalimab combined with chemotherapy in the treatment of locally advanced or metastatic non-small cell lung cancer |
| 摘要： | 目的 评价特瑞普利单抗（Tor）联合化疗用于局部晚期或转移性非小细胞肺癌（NSCLC）的有效性、安全性和经济性。方法检索PubMed、theCochraneLibrary、Embase、WebofScience、中国生物医学文献服务系统、中国知网、万方数据以及卫生技术评估（HTA）相关网站，收集Tor+化疗用于局部晚期或转移性NSCLC的HTA报告、系统评价/Meta分析和药物经济学研究，检索时限为建库或建站至2025年3月31日。提取资料、评价质量后，对纳入研究的结果进行描述性分析。结果共纳入11篇文献，包括系统评价/Meta分析5篇、药物经济学研究6篇。5篇系统评价/Meta分析中，高质量为2篇，中等、低和极低质量各1篇；6篇药物经济学研究的质量均良好。有效性方面，与化疗比较，Tor+化疗可显著延长患者的无进展生存期和总生存期（P＜0.05）；与伊匹木单抗+化疗、度伐利尤单抗、度伐利尤单抗+替西木单抗、舒格利单抗+化疗比较，Tor+化疗可显著延长患者的无进展生存期（P＜0.05）。安全性方面，Tor+化疗患者≥3级不良事件的发生率与化疗患者比较，差异无统计学意义（P＞0.05）；而与卡瑞利珠单抗+化疗、帕博利珠单抗+伊匹木单抗、纳武利尤单抗+化疗、阿替利珠单抗+化疗比较，Tor+化疗患者≥3级不良事件的发生率更低（P＜0.05）。经济性方面，与化疗比较，Tor+化疗具有经济学优势。结论与化疗、其他程序性死亡受体-1/程序性死亡受体配体-1抑制剂单用或联合化疗比较，Tor+化疗用于局部晚期或转移性NSCLC的有效性、安全性和经济性均较好。 |
| ABSTRACT： | OBJECTIVE To evaluate the efficacy， safety and cost-effectiveness of toripalimab （Tor） combined with chemotherapy （CT） in the treatment of locally advanced or metastatic non-small cell lung cancer （NSCLC）. METHODS PubMed， the Cochrane Library， Embase， Web of Science， CBM， CNKI， Wanfang Data， and Health Technology Assessment （HTA） related websites were searched to collect the HTA reports， systematic reviews/meta-analyses and pharmacoeconomic studies of Tor+CT in the treatment of locally advanced or metastatic NSCLC from database/website inception to March 31， 2025. After data extraction and quality evaluation， the results of the included studies were analyzed descriptively. RESULTS A total of eleven studies were included， involving five systematic reviews/meta-analyses， and six pharmacoeconomic studies. Among the five systematic reviews/ meta-analyses， two were of high quality， while there was one each of moderate， low， and very low quality. All six pharmacoeconomic studies were of good quality. In terms of efficacy， compared with CT， Tor+CT significantly improved patients’ progression-free survival （PFS） and overall survival （P＜0.05）. In addition， compared with ipilimumab+CT， durvalumab， durvalumab+tremelimumab and sugemalimab+CT， Tor+CT could also improve the PFS （P＜0.05）. In terms of safety， there was no significant difference in the incidence of grade≥3 adverse events between patients receiving Tor+CT and CT （P＞0.05）； while Tor+CT had a lower incidence of grade≥3 adverse E-mail： events， compared with camrelizumab+CT， pembrolizumab+ 3233255290@qq.com ipilimumab， nivolumab+CT and atezolizumab+CT （P＜0.05）.In terms of cost-effectiveness， Tor+CT treatment had certain cost-effectiveness advantages， compared with CT. CONCLUSIONS Compared with CT， other programmed death-1/programmed death-ligand 1 inhibitors alone， or their combination with CT， Tor+CT for the treatment of locally advanced or metastatic NSCLC has good efficacy， safety and cost-effectiveness. |
| 期刊： | 2025年第36卷第20期 |
| 作者： | 杨钰萍；周媛；台琪瑞；施米丽；师亦洁；王婕雅；胡欢；张园；刘一；王跃 |
| AUTHORS： | YANG Yuping， ZHOU Yuan，TAI Qirui，SHI Mili，SHI Yijie，WANG Jieya，HU Huan，ZHANG Yuan，LIU Yi，WANG Yue |
| 关键字： | 特瑞普利单抗；化疗；非小细胞肺癌；晚期；转移；快速卫生技术评估 |
| KEYWORDS： | toripalimab； chemotherapy； non-small cell lung cancer； advanced stage； metastasis； rapid health technology |
| 阅读数： | 9 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
